LIH383 (TFA)

LIH383 TFA is an agonist of ACKR3 (CXCR7) (EC50=0.61 nM) . LIH383 TFA efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling[1].

Product Specifications

UNSPSC

12352209

Target

CXCR

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Purity

99.83

Smiles

O=C(NCC(NCC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCSC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)[C@H](CC2=CC=CC=C2)N.O=C(O)C(F)(F)F.[x]

Molecular Formula

C45H72N16O8S.xC2HF3O2

Molecular Weight

997.22 (free base)

References & Citations

[1]Meyrath M, et al. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nat Commun. 2020 Jun 19;11 (1) :3033.